SmithKline Beecham
GSK’s Blenrep Demonstrates Survival Advantage Over J&J’s Darzalex in Multiple Myeloma Treatment
GSK, Blenrep, Belantamab mafodotin, Multiple myeloma, DREAMM-7, DREAMM-8, Darzalex, Survival advantage, Regulatory challenges
GSK Enters Strategic Alliance with Vesalius Therapeutics for Parkinson’s Disease Treatments
GSK, Vesalius Therapeutics, Parkinson’s disease, neurodegenerative diseases, strategic alliance, small molecule program
GSK Exits Biotechnology Innovation Organization (BIO) for 2025, Joining Takeda, UCB, and Others
GSK, BIO, Biotechnology Innovation Organization, Takeda, UCB, Pfizer, WuXi AppTec, AbbVie, pharmaceutical industry, trade group, lobbying
GSK’s Vaccine Sales Plummet in Q3, Highlighting Reduced Demand and Market Challenges
GSK, vaccine sales, third quarter, reduced demand, Arexvy, Shingrix, influenza vaccine
GSK Shifts Focus from Acquired Vaccine to Preclinical Successor Due to Increased Competition
GSK, vaccine, preclinical successor, increased competition, pneumococcal vaccine, Affinivax, MAPS technology
GSK Expands Lupus Portfolio with $300M Upfront Deal for T-Cell Engager
GSK, lupus, T-cell engager, Chimagen Biosciences, autoimmune diseases, pharmaceutical deals
GSK’s Arexvy RSV Vaccine Shows Promise in Younger Adults, Following Pfizer’s Approval
GSK, Arexvy, RSV vaccine, younger adults, Pfizer, ABRYSVO, respiratory syncytial virus, lower respiratory tract disease
GSK Invests $800 Million in Pennsylvania Site Expansion to Boost Vaccine and Medicine Production
GSK, Pennsylvania, manufacturing expansion, vaccine production, medicine manufacturing, $800 million investment
GSK and Cambridge University Collaborate on $65M Research Initiative to Combat Immune-Related Kidney and Lung Diseases
GSK, Cambridge University, Immune-related diseases, Kidney diseases, Lung diseases, Research collaboration, $65M deal
GSK, Sanofi, and CSL Secure $72 Million BARDA Funding to Enhance Bird Flu Vaccine Supply
BARDA funding, bird flu vaccine, GSK, Sanofi, CSL, vaccine supply, public health